2026-05-27T11:58:52-05:00 2025-12-31 112442493 CRAIG FITZSIMMONS & MEYER LLP 20 MANOR ROAD SMITHTOWN NY 11787 990 2025-01-01 582404527 LYMPHATIC EDUCATION & RESEARCH NETWORK INC (LE&RN) LYMP 5166259675 154 West 14th Street 2nd Floor NEW YORK NY 10011 WILLIAM REPICCI PRESIDENT & CEO 5166259675 2026-05-27 1 Robert Craig P01239055 6313601400 2025 2025-03-06 01:10:19Z X WILLIAM REPICCI 154 West 14th Street 2nd Floor NEW YORK NY 10011 4195141 0 X http://lymphaticnetwork.org X 1998 NY THE ORGANIZATION'S MISSION IS TO FIGHT LYMPHATIC DISEASE AND LYMPHEDEMA THROUGH EDUCATION, RESEARCH AND ADVOCACY. THE ORGANIZATION SEEKS TO ACCELERATE THE PREVENTION, TREATMENT, AND CURE OF LYMPHATIC DISEASES WHILE BRINGING PATIENTS AND MEDICAL PROFESSIONALS TOGETHER TO ADDRESS THE UNMET NEEDS SURROUNDING LYMPHATIC DISORDERS. 6 6 10 6 0 0 1558455 1142651 0 0 146764 113511 50591 27059 1755810 1283221 13348 23618 0 0 799985 1158508 0 0 164192 838053 588379 1651386 1770505 104424 -487284 4009793 3590003 411086 465304 3598707 3124699 X THE ORGANIZATION'S MISSION IS TO FIGHT LYMPHATIC DISEASES AND LYMPHEDEMA THROUGH EDUCATION, RESEARCH AND ADVOCACY. THE ORGANIZATION SEEKS TO ACCELERATE THE PREVENTION, TREATMENT, AND CURE OF LYMPHATIC DISEASES WHILE BRINGING PATIENTS AND MEDICAL PROFESSIONALS TOGETHER TO ADDRESS THE UNMET NEEDS SURROUNDING LYMPHATIC DISORDERS. 0 0 1442732 23618 1169710 Some activities of the organization during 2025 include the following: LE&RN continued to expand programs to meet the goals of the expanded mission of fighting lymphatic disease through education, research, and advocacy. LE&RN continued its grant program, which allows young investigators to attend conferences focused on lymphatic research. LE&RN continued its educational and awareness outreach programs targeting academia, government, industry, and the medical and patient communities. LE&RN continued its monthly virtual symposium series, which brings the world's foremost authorities in lymphatic disease and lymphedema to patients, their families, and professionals. LE&RN updated its website and provided daily social media posts and monthly newsletters featuring significant events in the field. LE&RN produced six issues of Lymphatic Research and Biology, an international, peer-reviewedbiomedical journal providing a forum for the exchange of cutting-edge scientific developments in lymphatic science and medicine. LE&RN secured ongoing support from the Congressional and National Institutes of Health for lymphatic research. LE&RN continued the LE&RN/LymphNotes Lymphedema Scholarship Program to provide tuition support to therapists seeking certification in lymphedema therapy. LE&RN continued a web-based "Ask the Experts" feature that allows patients, their families, and professionals to ask the most prominent authorities in the field questions directly. LE&RN spokesperson and Academy Award Winner Kathy Bates appeared in print and television media to support research. LE&RN's Virtual Expo was expanded to better serve patients and therapists. LE&RN and NAVBO prepared a biennial Virtual Lymphatic Forum for researchers LE&RN developed new chapters in several states and countries. LE&RN continued to lead global events related to its establishment of World Lymphedema Day on March 6, 2016. LE&RN supported and grew its Centers of Excellence in the Diagnosis & Treatment of Lymphatic Diseases to 80 member institutions in over 20 countries. LE&RN, in collaboration with Stanford University, hosted the annual virtual State-of-the-Art Summit in Lymphatic Research & Medicine. LE&RN promoted its PSA video featuring National Spokesperson Kathy Bates, which was hosted on the Centers for Disease Control and Prevention (CDC) 's cancer-related websites. LE&RN continued its cancer-related lymphedema campaign. LE&RN succeeded in having the Congressionally Directed Medical Research Program (CDMRP) include lymphedema as a category in the Department of Defense's Peer Reviewed Medical Research Program (PRMRP). LE&RN successfully requested that Congress establish a National Commission on Lymphatic Diseases at the National Institutes of Health (NIH). LE&RN established a global Patient Resource Center. LE&RN expanded and updated its Global Patient Registry. LE&RN successfully advocated for a Program Manager in Lymphatics at the Advanced Research Agency for Health (ARPA-H) LE&RN, in concert with the research community, created a "Gaps in Lymphatic Research" document that was distributed to the NIH, CDC, ARPA-H, CDMRP, NNLBI, and NIAID. LE&RN hired its first full-time Vice President of Scientific Affairs and Science and Medical Director. 1442732 1 1 0 1 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 3 0 10 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 6 6 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 0 0 AL AK CA CT DE FL GA IA ID IL IN KS LA MA MD MI MO MT NC NH AR NV NY OH OK OR PA SC TN VA VT WA WV WY AK WI WY CO DC HI KY ME MS NE NJ NM ND RI SD TX X X THE ORGANIZATION 5166259675 154 West 14th Street 2nd Floor NEW YORK NY 10011 X JOSEPH DAYAN MD DIRECTOR 1.00 X 0 0 0 Dr Emily Iker DIRECTOR 1.00 X 0 0 0 MELISSA ALDRICH PHD CHAIRPERSON 10.00 X X 0 0 0 RICK PETTY DIRECTOR 1.00 X 0 0 0 Liz Basaca TREASURER 1.00 X 0 0 0 DORON ILAN MD SECRETARY 1.00 X 0 0 0 Jonathan Ross DIRECTOR 1.00 X 0 0 0 WILLIAM REPICCI PRESIDENT & CEO 40.00 X 314640 0 57767 Maria Celia Dupecher Vice President for Scientific Affairs 40.00 X 146250 0 0 460890 0 57767 2 0 1 0 0 112500 1030151 1142651 21474 21474 3000000 2907963 92037 92037 92037 31016 3957 27059 27059 1283221 0 0 140570 23618 23618 460890 413694 31464 15732 494303 366495 18885 108923 30000 25500 3000 1500 108339 87470 4327 16542 64976 53016 3469 8491 49830 49830 76427 76427 11576 11576 5895 4774 443 678 31234 25292 2349 3593 29233 23672 2198 3363 42085 42085 3676 2977 276 423 RESEARCH & PROGRAM ACTI 292371 292371 DUES AND MEMBERSHIP 18725 14537 4188 FILING AND REGISTRATION 13097 13097 BANK AND CREDIT CARD FE 7634 7634 6596 5341 496 759 1770505 1442732 163581 164192 650953 288399 19303 199094 45000 22500 0 20094 14619 3900 3900 0 0 3273665 3064613 778 778 4009793 3590003 84068 63917 327018 371387 0 30000 411086 465304 X 3198707 2425199 400000 699500 3598707 3124699 4009793 3590003 -487284 13276 0 X 0 1 X 1 0 X 4128787 1433227 1427587 1609046 1169710 9768357 4128787 1433227 1427587 1609046 1169710 9768357 0 0 0 9768357 294 29306 48778 144745 113511 336634 294 29306 48778 144745 113511 336634 605 605 4129686 1462533 1476365 1753791 1283221 10105596 0.96660 0.97690 0.03330 0.02300 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 0 0 1 76427 76427 0 Part II-B, Line 1: Use of lobbyist/ consultant 3900 3900 0 0 CHARLES SCHWAB 371387 F Fidelity Investment 2693226 F 3064613 Refundable advances 30000 30000 X 1296497 13276 13276 1283221 0 1283221 1770505 0 1770505 0 1770505 Part X, Line 2: UNDER ACCOUNTING STANDARDS CODIFICATION (ASC) SECTION 740, THE TAX STATUS OF TAX-EXEMPT ENTITIES IS AN UNCERTAIN TAX POSITION, SINCE EVENTS COULD POTENTIALLY OCCUR THAT JEOPARDIZE THE ORGANIZATION'S TAX EXEMPT STATUS. MANAGEMENT OF THE ORGANIZATION IS NOT AWARE OF ANY EVENTS THAT COULD JEOPARDIZE ITS TAX-EXEMPT STATUS. THEREFORE, NO LIABILITY OR PROVISION FOR INCOME TAX HAS BEEN REFLECTED IN THE FINANCIAL STATEMENTS X X X X X AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY WALKATHONS 31016 31016 3957 31016 31016 3957 3957 27059 0 Lymphedema Therapist Scholarship 15 23618 1 X X X X 0 1 0 0 0 0 0 0 0 WILLIAM REPICCI PRESIDENT & CEO 283640 0 0 0 31000 0 30000 0 27767 0 372407 0 0 0 MICHAEL MINICHIELLO CEO's Spouse 95750 Consulting service related to the design of LE&Rn's website, brochurers, social media and conference events 0 Form 990, Part VI, Section B, line 11b THE BOARD TREASURER REVIEWS THE 990 IN DETAIL AND REVIEWS THE HIGHLIGHTS OF THE 990 WITH THE BOARD Form 990, Part VI, Section B, line 12c BOARD MEMBERS AND KEY MEMBERS OF MANAGEMENT ARE REQUIRED TO ANNUALLY SIGN A PROACTIVE CONFLICT OF INTEREST STATEMENT. BOARD MEMBERS AND KEY MEMBERS OF MANAGEMENT ARE REGULARLY REMINDED OF THEIR RESPONSIBILITIES WITH RESPECT TO THEIR INVOLVEMENT WITH THE ORGANIZATION AND THE NEED TO DISCLOSE REAL OR PERCEIVED CONFLICTS. Form 990, Part VI, Section B, line 15a ON AN ANNUAL BASIS THE BOARD DOES A COMPARISON STUDY BASED UPON PUBLISHED SALARY SURVEYS TO DETERMINE A REASONABLE COMPENSATION FOR THE PRESIDENT & CEO TAKING INTO CONSIDERATION PERFORMANCE, INDUSTRY NORMS, AND UNIQUE ASPECTS OF HIS RESPONSIBILITIES AT THE ORGANIZATION. Form 990, Part VI, Section C, line 19 THE ORGANIZATON MAKES ITS FINANCIAL STATEMENTS, ITS CONFLICTS OF INTEREST POLICY, AND ITS GOVERNING DOCUMENTS AVAILABLE FOR PUBLIC INSPECTION AT ITS CORPORATE OFFICE DURING NORMAL BUSINESS HOURS Form 990, Part VII, Section A Return was amended to properly list the 2025 Officers and Directors